A review on applications of abatacept in systemic rheumatic diseases.
Sign Up to like & getrecommendations! Published in 2021 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2021.107612
Abstract: Abatacept is a CTLA-4Ig fusion protein that selectively modulates the CD80/CD86:CD28 costimulatory pathway required for full T-cell activation. The FDA has approved it to be used to treat adult rheumatoid arthritis, juvenile idiopathic arthritis, and… read more here.
Keywords: review applications; abatacept systemic; rheumatic diseases; applications abatacept ... See more keywords